:: دوره 7، شماره 4 - ( 9-1397 ) ::
جلد 7 شماره 4 صفحات 4-1 برگشت به فهرست نسخه ها
Homocysteine and Folic Acid Prescription Effects on Cardiovascular Diseases
چکیده:   (6822 مشاهده)
Introduction: Homocysteine, is a sulfhydryl-containing amino acid that is typically present in very small amounts in all cells of the body.  Many investigations have indicated hyperhomocystenemia as a risk factor, which is correlated with complications such as atherosclerosis, cardiovascular disease (CVD), and stroke. The aim of the present work was to review different studies for   the lowering effect/s of folic acid supplementation on plasma homocysteine levels.
Methods: An academic search was conducted in  number of electronic databases such as EMBASE, PubMed, and etc. for the  key words; homocysteine , vitamin B12 , vitamin B6 , folic acid (vitamin B9)  and cardiovascular diseases  during years 2004 to  2018.
Findings: Review of the selected papers indicated that increased homocysteine levels as a risk marker for cardiovascular diseases, is associated with atheriosclerotic outcomes. In addition, it is considered   a higher risk of coronary artery disease in patients with chronic renal dysfunction. In apparent contrast, however, another study indicated  no risk reduction  in homocysteine-lowering trials based on prescription of folic acid and concluded that intake of high amounts of folic acid may be beneficial via the homocysteine lowering, but may also be harmful via destabilization the atherosclerotic plaque.
Conclusion: The authors conclude uncertainty of whether or not folic acid means of homocysteine lowering forms of therapy will reduce the risk of CVD remains a main focus of future research works.
     
نوع مطالعه: پژوهشي | موضوع مقاله: عمومى


XML     Print



بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.
دوره 7، شماره 4 - ( 9-1397 ) برگشت به فهرست نسخه ها